Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of TLC-2716 in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TLC-2716 (Primary)
Indications Dyslipidaemias; Hypercholesterolaemia; Hypertriglyceridaemia; Non-alcoholic steatohepatitis
Focus Adverse reactions; First in man
Sponsors The Liver Company

Most Recent Events

17 May 2024 Status changed from active, no longer recruiting to completed.
13 Nov 2023 Results (n=100) assessing Safety, Pharmacokinetics, and Lipid Lowering Effects of the Oral, Liver-Targeted Liver X Receptor (LXR) Inverse Agonist TLC-2716 in Healthy Volunteers presented at the American Heart Association Scientific Sessions 2023
06 Nov 2023 Results presented in the OrsoBio Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com